The company is facing a securities class action lawsuit for allegedly making materially false and misleading statements about clinical trial data. The stock experienced a 64% single-day crash after FDA documents revealed undisclosed modifications to the statistical analysis plan, and the drug failed to meet pre-specified efficacy endpoints.
The company is the subject of a securities fraud lawsuit alleging material misstatements and omissions regarding regulatory prospects for its lead drug candidate. Stock experienced severe declines (64% and 36%) following FDA and AdCom panel rejections of the drug's efficacy, indicating significant business and legal risks.
The company is accused of making false and misleading statements to the market regarding clinical data analysis for its drug candidate without FDA approval, resulting in investor losses and a securities fraud lawsuit.
The company is accused of making materially false and misleading statements about its drug candidate Deramiocel and failing to disclose that the FDA had not approved changes to its statistical analysis plan before resubmitting its BLA, creating substantial risk of regulatory rejection and investor losses.
The company faces a class action lawsuit alleging material misstatements and omissions regarding undisclosed changes to clinical trial analysis plans. The FDA rejected the drug candidate's efficacy claims, resulting in a 64% stock decline on July 27 and an additional 36% decline on July 30, 2026, indicating severe regulatory and financial setbacks.
The company is the subject of a securities class action lawsuit alleging material misstatements regarding clinical trial data and undisclosed SAP modifications. The stock experienced a 64% single-day crash after FDA briefing documents revealed the HOPE-3 study failed to meet pre-specified primary and secondary efficacy endpoints, resulting in significant investor losses.
The company faces a class action lawsuit for failing to disclose material information about undisclosed changes to its statistical analysis plan. The FDA found the modifications were post-hoc and exploratory without scientific justification, leading to an unfavorable benefit-risk profile for its lead drug candidate. The stock declined 64% following the FDA disclosure.
Company made materially false and misleading statements about FDA approval of statistical analysis plan changes for its lead drug candidate. FDA rejected the drug citing unfavorable benefit-risk assessment. Stock price fell 64% on July 27, 2026, and an additional 36% on July 30, 2026, following FDA advisory committee vote against efficacy.
The company faces a securities fraud lawsuit for allegedly concealing changes to statistical analysis plans and failing to disclose FDA concerns about data integrity. The stock declined 62% following FDA briefing documents criticizing the methodology, and an advisory panel rejected the efficacy of its lead drug candidate Deramiocel.
Company is accused of making materially false and misleading statements regarding its Deramiocel cell therapy, failing to disclose unauthorized changes to statistical analysis plans and lack of FDA pre-approval, creating substantial regulatory risk. This resulted in investor losses.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding clinical trial data analysis and FDA regulatory approval risks for its Deramiocel therapy. Investors who purchased during the class period allegedly suffered damages when the true details entered the market.
The company is facing securities fraud allegations for misstatements about its lead product and clinical data integrity. The stock experienced a severe 64.5% drop following FDA concerns about statistical analysis changes, and an FDA advisory committee voted against the efficacy of Deramiocel, resulting in additional stock decline.
The company is accused of making materially false and misleading statements regarding its Deramiocel cell therapy, failing to disclose changes to statistical analysis plans, and concealing FDA concerns about regulatory approval. These allegations resulted in investor losses and triggered a securities class action lawsuit.
Positive phase III HOPE-3 data demonstrating 54% reduction in upper-limb function decline, FDA acceptance of resubmission with refined indication, and renewed regulatory pathway provide a clear catalyst for approval. However, Zacks Rank #3 (Hold) reflects remaining regulatory risk and the possibility of another CRL.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding undisclosed changes to clinical trial analysis plans without FDA agreement, creating substantial regulatory approval risk for its lead therapeutic candidate Deramiocel. Investors who purchased during the class period are seeking compensation for losses.
The company is accused of making materially false and misleading statements about clinical trial data, made undisclosed post-hoc modifications to its statistical analysis plan without FDA agreement, and its lead drug failed to meet pre-specified efficacy endpoints. The stock experienced a 64% single-day collapse, and an Advisory Committee voted against the drug's efficacy. A securities class action lawsuit is ongoing.
The company is accused of material misstatements and omissions regarding its lead product's statistical analysis plan and FDA compliance. The FDA disagreed with undisclosed changes to the analysis methodology, resulting in an unfavorable benefit-risk assessment. The stock declined 64% following the FDA's public disclosure of these issues, indicating significant loss of investor confidence and regulatory setback.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding undisclosed changes to clinical trial analysis plans and lack of FDA agreement before BLA resubmission, creating substantial regulatory risks for its lead therapeutic candidate.
The company is the subject of a class action lawsuit alleging material misstatements and non-disclosure of critical information regarding FDA regulatory approval risks for its lead drug candidate Deramiocel. The allegations suggest deliberate or reckless concealment of adverse facts about business prospects.
Company faced significant regulatory scrutiny when FDA documents revealed undisclosed changes to statistical analysis plans for a drug application, leading to a severe 64% stock price decline and triggering a class action lawsuit for investor losses.
The company experienced a major regulatory setback with a 9-3 negative Advisory Committee vote on its primary cardiomyopathy indication, despite positive primary endpoint data on upper limb function. While management is pursuing an alternative regulatory pathway, the company faces significant cash burn ($40.7M net loss in Q2), declining cash reserves (from $318.1M to $237.9M), and ongoing disputes with its distribution partner NS Pharma. The stock declined 14.35% following the announcement.
The company faces allegations of making false and misleading statements regarding FDA approval processes and clinical trial data integrity. The stock experienced significant declines (64% and 36%) following FDA briefing documents and advisory committee decisions against the lead drug candidate's efficacy, indicating serious regulatory and commercial setbacks.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding clinical trial data analysis and FDA regulatory approval risks for its lead drug candidate Deramiocel. These allegations suggest potential fraud and regulatory setbacks that would negatively impact investor value.
The company is the subject of a securities class action lawsuit alleging material misstatements and omissions regarding regulatory compliance and clinical trial data integrity for its lead therapeutic candidate, indicating serious legal and regulatory risks.
The company is the subject of a securities fraud class action lawsuit alleging material misrepresentations about business operations and financial stability, resulting in artificially inflated stock prices and significant investor losses during the class period.
The company faces a securities class action lawsuit for allegedly concealing material information about undisclosed changes to its drug's statistical analysis plan. The FDA rejected the drug application, and the stock experienced severe declines of 64% and 36% on consecutive trading days, indicating significant loss of investor confidence and regulatory setback.
The company faces allegations of issuing materially misleading business information. FDA staff raised significant concerns about the effectiveness data of its experimental therapy, resulting in a 64-65% stock price decline. A securities class action lawsuit is being prepared against the company.
The FDA reported that the company's lead therapeutic candidate failed to meet Phase 3 trial objectives, contradicting prior company claims. This represents a significant setback for the company's primary product pipeline and resulted in immediate stock price decline, indicating loss of investor confidence and potential regulatory/commercial challenges ahead.
Company faces federal securities investigation for potential disclosure violations, experienced 64% stock price decline, and received unfavorable FDA Advisory Committee vote (3-9) on its lead drug candidate, raising significant concerns about regulatory approval prospects and investor confidence.
The company's investigational drug failed to gain FDA approval with a 9-3 advisory panel vote against it. The FDA raised concerns about effectiveness data and the company's post-hoc changes to how trial results were measured. The stock experienced a catastrophic 67% decline followed by an additional 50% drop, indicating severe loss of investor confidence and potential securities fraud investigation.
Stock plummeted 64% following FDA disclosure that the HOPE-3 trial failed to meet pre-specified efficacy endpoints, contradicting the company's December 2025 positive announcement. Investigation alleges misleading investor disclosures regarding trial results and undisclosed changes to statistical analysis plans.
FDA staff raised significant concerns about the effectiveness data and methodology of the company's experimental therapy, questioning the scientific validity of post-trial measurement changes. The stock experienced a severe 70% decline following these revelations, and the company is now under securities investigation for potential misrepresentation or failure to disclose material information.
Company is under investigation for securities fraud due to allegedly misleading investors about regulatory approval prospects for its drug candidate. FDA determined the therapy lacks substantial evidence of effectiveness, and the company made post-hoc changes to its statistical analysis plan, raising concerns about data manipulation. Stock price fell over 60% on the news.
The insider sale is part of a routine pre-planned trading arrangement and not a bearish signal. While the stock has declined 30% year-to-date, the article notes Wall Street analysts are bullish on the upcoming FDA decision expected in August 2026, which could be a significant positive catalyst. The company's success depends on clinical trial outcomes and regulatory approval, creating inherent uncertainty typical of clinical-stage biotech.
The insider sale was executed under a pre-scheduled trading plan established months in advance, indicating a routine diversification move rather than a loss of confidence in the company. The insider retained significant equity exposure (30,547 shares and 56,261 options), and the article emphasizes this was not a 'quiet exit' but a structured transaction. The real investment question centers on whether the clinical pipeline justifies current valuation after the stock's 335% one-year run, not on the insider's conviction.
Articles that tag CAPR but are mainly about other companies.
Company is subject to a class action lawsuit alleging misleading financial statements that caused significant stock price decline for investors.
Company is subject to a pending securities class action lawsuit with a lead plaintiff deadline of September 28, 2026, indicating alleged securities violations during the December 17, 2025 - July 26, 2026 period.
Subject of class action lawsuit filed by Pomerantz LLP for alleged securities fraud or unlawful business practices, though specific details are not provided in the article excerpt.
Company is subject to securities class action lawsuit with investors encouraged to secure counsel before important deadline, indicating alleged securities violations.
Company is subject to securities class action lawsuit with investors having losses exceeding $100K, indicating material investor harm and alleged securities violations.
Company is subject to a securities class action with investors who suffered losses exceeding $100,000, indicating significant shareholder harm from alleged securities violations.
Company is subject to a class action securities fraud lawsuit with a September 28, 2026 application deadline for lead plaintiff status, indicating alleged securities violations and investor losses.
Alert regarding investor losses and ongoing lawsuit investigation indicates significant shareholder concerns and potential legal liability for the company.
Company is involved in a shareholder lawsuit covering the period December 17, 2025 to July 6, 2026, indicating alleged misconduct that caused investor losses.
Alert regarding investor losses and ongoing lawsuit investigation indicates significant shareholder concerns and potential legal liability.
Investors with large losses are being solicited to discuss their rights, indicating significant shareholder losses and potential legal action.
Investors with large losses are being solicited to discuss their rights regarding a lawsuit, indicating significant shareholder losses and legal action against the company.
Company is subject to a securities class action lawsuit with investors who purchased shares between December 17, 2025 and July 6, 2026 experiencing significant losses.
Leading the DMD pipeline with CAP-1002 in registered/late-stage development, demonstrating advanced progress in cell replacement therapy for DMD treatment.
Articles and sentiment ratings from Massive / Polygon. Sentiment is the provider's model rating for this company, not Gainbot's view.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
